Articles related to PEDIATRIC CANCER

Silent inactivation (where neutralizing antibodies reduce enzymatic activity without clinical symptoms) can go undetected without therapeutic drug monitoring, leading to subtherapeutic asparagine depletion and increased relapse risk.

Cancer incidence rates increased for several cancer types in many of the countries studied; however, other than colorectal cancer, these increases occurred in both younger and older adults.

SEER registry analysis revealed striking birth cohort effects with appendiceal adenocarcinoma rates more than quadrupling in the 1985 birth cohort compared to the 1945 reference group.

Reed-Sternberg cells harbor chromosome 9p24 amplification encoding PD-1 ligand, creating therapeutic vulnerability exploited by checkpoint inhibitors with remarkable clinical responses.

Age bias in oncology can lead to younger patients receiving more aggressive treatments with marginal survival benefits, potentially compromising their quality of life.

In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.